Cas:716362-28-6 2-amino-5-fluoro-1H-benzimidazole-4-carboxylic acid manufacturer & supplier

Chemical Name:2-amino-5-fluoro-1H-benzimidazole-4-carboxylic acid

CAS.NO:716362-28-6

Synonyms:1h-benzimidazole-4-carboxylic acid,2-amino-5-fluoro;1H-Benzimidazole-4-carboxylicacid,2-amino-5-fluoro-(9CI);1H-Benzimidazole-7-carboxylicacid,2-amino-6-fluoro

Molecular Formula:C₈H₆FN₃O₂

Molecular Weight:195.15100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:92.73000

Exact Mass:195.04400

LogP:0.91250

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1h-benzimidazole-4-carboxylic acid,2-amino-5-fluoro chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Benzimidazole-7-carboxylicacid,2-amino-6-fluoro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Benzimidazole-4-carboxylicacid,2-amino-5-fluoro-(9CI) Use and application,1H-Benzimidazole-4-carboxylicacid,2-amino-5-fluoro-(9CI) technical grade,usp/ep/jp grade.

Related News: A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 2-amino-5-fluoro-1H-benzimidazole-4-carboxylic acid manufacturer The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 2-amino-5-fluoro-1H-benzimidazole-4-carboxylic acid supplier Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers. 2-amino-5-fluoro-1H-benzimidazole-4-carboxylic acid vendor A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 2-amino-5-fluoro-1H-benzimidazole-4-carboxylic acid factory ��Administrative Measures for the Joint Review, Review and Approval of Raw Materials, Medicinal Auxiliaries and Pharmaceutical Packaging Materials and Pharmaceutical Preparations�� (Consultation Draft) issued by the State Food and Drug Administration in December 2017. Supervision departments no longer accept applications for registration of APIs, pharmaceutical excipients, and packaging materials.